References
- Mallick U, Harmer C, Yap B et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N. Engl. J. Med. 366(18), 1674–1685 (2012).
- Zanotti-Fregonara P, Hindié E. On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging 37(12), 2264–2266 (2010).
- Van Nostrand D, Khorjekar GR, O’Neil J et al. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET. J. Nucl. Med. 53(3), 359–362 (2012).
- Rosario PW, Salles DS, Purisch S. Area under the curve of TSH after levothyroxine withdrawal versus administration of recombinant human TSH (rhTSH): possible implications for tumor growth. Arq. Bras. Endocrinol. Metabol. 53(6), 767–770 (2009).
- Tala H, Robbins R, Fagin JA, Larson SM, Tuttle RM. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J. Clin. Endocrinol. Metab. 96(7), 2105–2111 (2011).
- Hugo J, Robenshtok E, Grewal R, Larson S, Tuttle RM. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. Thyroid 22(10), 1007–1015 (2012).